Answers are grounded in this paper and cite their sources.
Case series reports notable symptom improvement in refractory trigeminal neuralgia after Suzetrigine treatment, suggesting a new therapeutic approach.
Suzetrigine selectively blocks the NaV1.8 voltage-gated sodium channel in peripheral neurons. Trigeminal neuralgia (TN) is a neuropathic pain syndrome affecting the trigeminal nerve and is traditionally treated with nonselective sodium channel blockers. No studies have evaluated Suzetrigine for TN, but potential involvement of NaV1.8 in TN signaling may represent a novel therapeutic target. We describe four patients with varying symptomatology of TN and previously failed responses to pharmacological and interventional treatments who exhibited notable symptomatic improvements with Suzetrigine, with no adverse effects. Further study is required in larger populations regarding the safety and efficacy of long-term Suzetrigine use for refractory TN.
No takes yet. Share an insight, caveat, or question.
Rayasam et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: